PROCEPT BioRobotics Corporation Common Stock
PRCTPROCEPT BioRobotics Corporation (PRCT) is a medical device company focused on developing innovative solutions for the treatment of benign prostatic hyperplasia (BPH). The company is known for its Water Vapor Therapy platform, which uses controlled water vapor to ablate excess prostate tissue, offering a minimally invasive option for patients. Founded to advance urological care, PROCEPT aims to improve patient outcomes with technology that simplifies BPH treatment procedures.
Company News
Procept BioRobotics reported strong Q2 2025 financial results with 48.3% revenue growth, reaching $79.2 million, driven by increased U.S. and international sales of robotic surgical systems for BPH treatment.
PROCEPT BioRobotics announced leadership transition with Dr. Reza Zadno retiring and Larry L. Wood becoming the new president and CEO effective September 2, 2025. The company also pre-announced Q2 2025 revenue of $79.2 million, representing 48% annual growth.
PROCEPT BioRobotics announced a new Category I CPT code for Aquablation therapy, effective January 1, 2026, with Medicare payment rates comparable to traditional TURP procedures, signaling broader recognition and potential adoption of their BPH treatment technology.
Several mid-cap stocks, including Globalstar, V.F. Corp, and Madrigal Pharmaceuticals, were among the top gainers last week. The companies reported positive financial results and business updates, leading to the stock price increases.
PROCEPT BioRobotics announced FDA clearance of its next-generation HYDROS Robotic System, which features AI-powered treatment planning, advanced image guidance, and robotic resection to deliver improved efficiency, enhanced user experience, and better clinical outcomes for Aquablation therapy.
